Navigation Links
Terumo Corporation, A Global Leader In Medical Device Technology, Celebrates 90th Anniversary
Date:9/29/2011

SOMERSET, N.J., Sept. 29, 2011 /PRNewswire/ -- Terumo Americas Holdings, Inc., a U.S. subsidiary of Terumo Corporation, today celebrates the 90th anniversary of Terumo Corporation's founding in 1921.  Terumo Corporation is one of the world's leading medical device manufacturers with $4 billion in annual sales and operations in more than 160 countries.

In August, Forbes magazine ranked Terumo Corporation 14th of the top 100 global companies on its "World's Most Innovative Companies" list.  According to Forbes, the rankings were based on findings from an eight year study led by a team of independent industry researchers who assessed each company an "innovation premium," a measure of investor expectation for future innovation such as new product development, services and market development.

"For 90 years, medical professionals have trusted Terumo Corporation, because our deep understanding of their practical, clinical, and economic needs enables us to implement insightful, 'people-friendly' solutions that contribute to better patient outcomes," said Kazuaki Kitabatake, President & CEO, Terumo Americas Holding, Inc. "We are thankful to our customers and Associates worldwide who are the driving force behind Terumo Corporation's strong, long-term stability and evolution as a leader in global healthcare."

Originally founded in Japan by several medical scientists intent on manufacturing the most reliable clinical thermometers, Terumo Corporation has evolved into a global leader in the development, manufacture, and distribution of world-class medical devices in high-growth therapeutic areas of cardiovascular medicine such as cardiothoracic surgery, left-ventricular assist systems for end-stage heart failure, minimally invasive coronary and endovascular interventions, and neuro-interventional technologies for cerebral aneurysms.

In 2011, Terumo strengthened its global portfolio with strategic acquisitions of CaridianBCT and Harvest Technologies Corp.  The acquisition of CaridianBCT elevates Terumo as the leader in blood processing technology, while Harvest Technologies provides access to the world's first point-of-care technology allowing physicians to derive highly concentrated autologous, adult stem cells from bone marrow that international human clinical studies have shown are highly effective in treating vascular, orthopedic and cardiovascular diseases.

According to Kitabatake, Terumo Corporation's mission is to contribute to the evolution of healthcare by maintaining close communication with customers worldwide.

"Terumo Corporation will continue to execute a comprehensive business strategy that combines innovative medical device technology with extensive educational and training support for healthcare professionals worldwide," said Kitabatake.

For more information about Terumo Corporation's 90th anniversary announcement, please contact Robert Murphy, The Storch-Murphy Group, at (908) 276-0777 or rmurphy@storchmurphy.com.

Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $4.0 billion in sales and operations in more than 160 nations.  Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.  Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.  Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543:  JP) and is a component of the Nikkei 225, Japan's leading stock index.


'/>"/>
SOURCE Terumo Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
2. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
3. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
4. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
5. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
6. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
7. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
8. Terumo to Sponsor Presentations on Key Issues in Cardiac and Vascular Surgery at Society of Thoracic Surgeons Annual Meeting
9. Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
10. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
11. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Research and Markets has announced the addition of ... & Biochemical Research, Disease Diagnostics), End User (Academic & Research Institutes, ... to their offering. ... , The western blotting market ... 574.8 Million in 2016, growing at a CAGR of 4.9%. ...
(Date:12/5/2016)... 5, 2016   BIOTRONIK today announced the ... study evaluates the safety and feasibility of performing the ... setting. BioMonitor 2 is an insertable cardiac ... placed underneath a patient,s skin to help physicians accurately ... fibrillation is a leading cause of stroke and heart ...
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
Breaking Medicine Technology:
(Date:12/6/2016)... , ... December 06, 2016 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:12/6/2016)... ... 06, 2016 , ... U.S. Security Associates (USA) was named ... their industry leading training methods that engage their associates and link their achievements ... elite in employer-sponsored training and development programs. , “The 2017 Training Top 125 ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... its latest transitional care facility – Avamere Transitional Care of Puget Sound ... foot short-term, post-acute health care center will provide patients recovering from illness or ...
(Date:12/5/2016)... St. Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... effects concussions have on the growing brains of young athletes. Over the course of ... to the head through unique mouth guards. The mouth guards, equipped with special sensors, ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
Breaking Medicine News(10 mins):